论文部分内容阅读
随机开放性研究左氧氟沙星与奈替米星联合治疗呼吸道铜绿假单胞菌感染 ,并与头孢他啶进行临床疗效的比较。 6 5例病人随机分为治疗组 35例 ,左氧氟沙星片 0 .2 g,bid,奈替米星针 0 .2～ 0 .3g,qd;对照组 30例 ,头孢他啶针 3～ 4,qd;均为 7～ 14d;评价其临床疗效及安全性。结果治疗组与对照组的用药天数分别为 (9.4± 3.3) d和 (8.5± 3.3) d(P>0 .0 5 ) ,两组资料无显著性差异 (P>0 .0 5 ) ;治疗组的临床总有效率为88.6 % ,对照组为 86 .6 % (P>0 .0 5 ) ;细菌清除率治疗组为 89.1% ,对照组为 87.0 % ,治疗期间未见明显与药物有关的不良反应。结论 ,左氧氟沙星、奈替米星和头孢他啶在治疗呼吸道绿铜假单胞菌感染方面有效、安全 ,临床疗效一致 ,值得推广。
A randomized open-label study of levofloxacin and netilmicin in the treatment of respiratory tract Pseudomonas aeruginosa infection was compared with ceftazidime for clinical efficacy. Sixty-five patients were randomly divided into treatment group 35 cases, levofloxacin tablets 0.2 g, bid, netilmicin needle 0 .2 ~ 0 .3 g, qd; control group of 30 patients, 3 to 4 days, ceftazidime, qd; For 7 ~ 14d; evaluate its clinical efficacy and safety. Results The days of treatment in the treatment group and the control group were (9.4 ± 3.3) days and (8.5 ± 3.3) days (P> 0.05), respectively. There was no significant difference between the two groups (P> 0.05) The total clinical effective rate was 88.6% in the control group and 86.6% in the control group (P> 0.05). The bacterial clearance rate was 89.1% in the treatment group and 87.0% in the control group, and no significant drug-related Adverse reactions. Conclusions: Levofloxacin, netilmicin and ceftazidime are effective, safe and consistent in the treatment of Pseudomonas aeruginosa infection in the respiratory tract, and are worthy of promotion.